SVIDENCE

Simplifying Progress

Conference Call Acquisition of Polyplus

Joachim Kreuzburg, René Fáber, Rainer Lehmann Sartorius | Sartorius Stedim Biotech | April 5, 2023



Polyplus at a glance



HQ in Strasbourg, France; Locations in Belgium, U.S., and China



- ~270 employees
- GMP manufacturing
- F) Founded in 2001



Portfolio


- Transfection as well as other DNA/RNA delivery reagents
- Plasmid DNA in high quality and GMP grade
- Key applications include production of viral vectors used in cell and gene therapies and other advanced medicinal therapeutic products

Positioning and financials

- Strongly growing and increasingly relevant end market
- Widely used products with significant win-rates and market shares
- Sales revenue 2023e in the upper double-digit million-euro range, strong growth rates
- Very substantial gross and EBITDA margins
- High share of recurring revenue, mission-critical product that is spec`d in early during the development process




Robust innovations for each stage of the workflow





Transfection reagents and plasmids are critical raw materials for the production of viral vectors

Viral vector upstream process



Transfection reagents and plasmids are mission-critical

plasmid design / / purity significantly impact yield
gent to plasmid for ideal results
ement for upstream process
optimization factor for the process




Combination of portfolios creates differentiated, fully integrated, and broad workflow solution to address pain points


Polyplus` solutions for transfection and plasmids



>




Sartorius` solutions for process development and manufacturing






Strengthen positioning in a high-growth segment

~45% of biopharma R&D pipeline is based on new modalities¹



Viral-based and Advanced Therapies markets growing particularly fast CAGRs 2022-2026²



Market dynamics

- Large and rapidly growing pipeline of gene and gene modified cell therapies as well as DNA/RNA therapeutics in development
- Maturing clinical pipelines driving significant demand for upstream process inputs and non-viral delivery reagents
- Indications with larger patient populations and expanded clinical applications of DNA/RNA beyond vaccines

1 Source: GlobalData, November 2022; 2 Sartorius` estimates excluding Corona vaccines and therapeutics



Significant synergy potential



Portfolio

- Highly complementary product portfolio without overlaps
- Further enhance relevance of our portfolio for advanced therapies
- Solve key pain points



- Access to customers in advanced therapies across the entire workflow
- Improve opportunities both upstream and downstream:
 - Cell culture media and media components
 - Monoliths for purification applications



Global platform

- Complementary R&D capabilities to create innovation
- Leverage sales organization and customer reach
- Utilize global manufacturing infrastructure



Key terms and timeline

€ Purchase price	 Approx. €2.4bn
Financing	 Bridge loan facility at Sartorius AG level for up to 2 years Refinancing mainly by long-term debt; depending on market conditions, a smaller portion potentially refinanced through a capital increase at Sartorius Stedim Biotech S.A.
60 Conditions	 Transaction subject to customary conditions, particularly approval by regulatory authorities
L Timeline	 Closing expected during Q3 2023



Questions & Answers





Disclaimer

This presentation contains statements concerning the future performance of the Sartorius and the Sartorius Stedim Biotech Groups. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions harbor risks and uncertainties that could lead to actual results substantially diverging from the expected ones. It is not planned to update our forward-looking statements.

Throughout this presentation, differences may be apparent as a result of rounding during addition.

